Targeting Immune Checkpoints in Hematologic Malignancies.
The use of antibodies that target immune checkpoint molecules on the surface of T-lymphocytes and/or tumor cells has revolutionized our approach to cancer therapy. Cytotoxic-T-lymphocyte antigen (CTLA-4) and programmed cell death protein 1 (PD-1) are the two most commonly targeted immune checkpoint molecules. Although the role of antibodies that target CTLA-4 and PD-1 has been established in solid tumor malignancies and Food and Drug Administration approved for melanoma and non-small cell lung cancer, there remains a desperate need to incorporate immune checkpoint inhibition in hematologic malignancies. Unlike solid tumors, a number of considerations must be addressed to appropriately employ immune checkpoint inhibition in hematologic malignancies. For example, hematologic malignancies frequently obliterate the bone marrow and lymph nodes, which are critical immune organs that must be restored for appropriate response to immune checkpoint inhibition. On the other hand, hematologic malignancies are the quintessential immune responsive tumor type, as proven by the success of allogeneic stem cell transplantation (allo-SCT) in hematologic malignancies. Also, sharing an immune cell lineage, malignant hematologic cells often express immune checkpoint molecules that are absent in solid tumor cells, thereby offering direct targets for immune checkpoint inhibition. A number of clinical trials have demonstrated the potential for immune checkpoint inhibition in hematologic malignancies before and after allo-SCT. The ongoing clinical studies and complimentary immune correlatives are providing a growing body of knowledge regarding the role of immune checkpoint inhibition in hematologic malignancies, which will likely become part of the standard of care for hematologic malignancies.
Departments of Stem Cell Transplantation and Cellular Therapy (G.A., E.A.M.), Leukemia (N.D.), and Breast Surgical (E.A.M.) Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas galatras@mdanderson.org.
Gheath
G
Alatrash
Departments of Stem Cell Transplantation and Cellular Therapy (G.A., E.A.M.), Leukemia (N.D.), and Breast Surgical (E.A.M.) Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Naval
N
Daver
Departments of Stem Cell Transplantation and Cellular Therapy (G.A., E.A.M.), Leukemia (N.D.), and Breast Surgical (E.A.M.) Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Elizabeth A
EA
Mittendorf
D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D060908:CTLA-4 Antigen; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000628:therapy*; D019337:Hematologic Neoplasms / Q000235:genetics / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000235:genetics / Q000628:therapy*
D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D060908:CTLA-4 Antigen
N Engl J Med. 2014 Dec 4;371(23):2189-2199
25409260
Eur J Immunol. 1998 Jan;28(1):90-103
9485189
Blood. 2013 Jan 10;121(2):308-17
23160468
Semin Oncol. 1993 Oct;20(5 Suppl 5):58-74
8211208
Immunol Rev. 2009 May;229(1):12-26
19426212
Blood. 1997 Dec 1;90(11):4297-306
9373240
Science. 2013 Dec 20;342(6165):1432-3
24357284
Science. 2016 Mar 25;351(6280):1463-9
26940869
Bone Marrow Transplant. 2016 Mar;51(3):443-5
26551782
Semin Hematol. 2001 Jul;38(3):243-9
11486312
Science. 2001 Jan 12;291(5502):319-22
11209085
Clin Cancer Res. 2012 Mar 15;18(6):1611-8
22271878
Leukemia. 2015 Jun;29(6):1441-4
25634684
Immunity. 2002 Jan;16(1):23-35
11825563
N Engl J Med. 2011 Aug 25;365(8):725-33
21830940
Immunity. 1994 Dec;1(9):793-801
7534620
Science. 2015 Apr 3;348(6230):124-8
25765070
Br J Haematol. 2003 Mar;120(6):1000-8
12648070
Science. 2015 Oct 9;350(6257):207-211
26359337
Blood. 2010 Oct 7;116(14):2484-93
20570856
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
24714771
Leukemia. 2007 Jul;21(7):1451-9
17508005
J Clin Oncol. 2011 Aug 1;29(22):3016-22
21730266
Blood. 2009 Feb 12;113(7):1581-8
18974373
Blood. 2013 Oct 24;122(17):3062-73
24030385
Clin Cancer Res. 2015 Oct 15;21(20):4607-18
25979485
Clin Cancer Res. 2011 Jul 1;17(13):4232-44
21540239
J Exp Med. 2000 Oct 2;192(7):1027-34
11015443
Blood. 2015 Jun 25;125(26):4017-23
25999455
Blood. 2010 Oct 28;116(17):3268-77
20628145
Immunity. 1999 Aug;11(2):141-51
10485649
Blood. 1994 Jun 15;83(12):3815-25
7515723
Blood. 2016 Feb 4;127(5):646-57
26670634
Leukemia. 2015 Jul;29(7):1621-2
25987102
Exp Hematol. 1999 Mar;27(3):479-88
10089910
Leukemia. 2014 Jun;28(6):1280-8
24270737
N Engl J Med. 2015 May 21;372(21):2018-28
25891174
Science. 2006 Sep 29;313(5795):1972-5
16931720
J Immunol. 2013 Oct 15;191(8):4121-9
24026081
Blood. 2007 Feb 1;109(3):1103-12
17023585
Blood. 2009 Aug 20;114(8):1528-36
19420358
Blood. 2012 Jun 14;119(24):5678-87
22538857
J Clin Oncol. 2001 Feb 1;19(3):720-6
11157023
Mod Pathol. 1990 May;3(3):361-7
2194216
Clin Cancer Res. 2013 Oct 15;19(20):5636-46
23873688
J Immunol. 2007 Nov 15;179(10):6547-54
17982043
Clin Cancer Res. 2008 May 15;14(10):3044-51
18483370
J Immunol. 2009 May 15;182(10):5938-48
19414745
Clin Cancer Res. 2009 Oct 15;15(20):6446-53
19808874
Ann Hematol. 2005 May;84(5):287-97
15592672
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11790-5
12195015
Blood. 2011 Jan 20;117(3):1030-41
21063028
N Engl J Med. 2015 Jul 2;373(1):23-34
26027431
J Clin Oncol. 2016 Mar 20;34(9):987-1011
26846975
Sci Transl Med. 2015 Sep 2;7(303):303ra139
26333935
N Engl J Med. 2007 Mar 15;356(11):1110-20
17360989
Cell Immunol. 2011;271(2):450-4
21907333
Bone Marrow Transplant. 1998 Nov;22(9):835-43
9827810
Oncotarget. 2013 Nov;4(11):2067-79
24162015
Blood. 2010 May 6;115(18):3655-63
20203260
Br J Haematol. 2003 Feb;120(3):442-51
12580958
J Exp Med. 2012 Jun 4;209(6):1201-17
22641383
J Exp Clin Cancer Res. 1997 Jun;16(2):171-6
9261743
Cancer Immunol Res. 2016 Jan;4(1):61-71
26464015
Lancet Oncol. 2014 Jan;15(1):69-77
24332512
Expert Opin Biol Ther. 2011 Apr;11(4):473-87
21269237
J Clin Oncol. 2013 Nov 20;31(33):4199-206
24127452
Nat Med. 2000 Sep;6(9):1018-23
10973322
J Exp Med. 2009 Dec 21;206(13):3015-29
20008522
N Engl J Med. 2016 Jul 14;375(2):143-53
27410923
Blood. 1998 Sep 1;92(5):1471-90
9716573
N Engl J Med. 2013 Apr 18;368(16):1509-1518
23527958
Exp Hematol. 2002 Feb;30(2):126-34
11823047
Blood. 1995 May 1;85(9):2607-18
7537122
N Engl J Med. 2015 Jan 22;372(4):311-9
25482239
J Immunol. 1997 Oct 1;159(7):3460-73
9317145
Science. 1996 Mar 22;271(5256):1734-6
8596936